SCENTMATIC
8.4.2024 11:32:26 CEST | Business Wire | Press release
SCENTMATIC Inc (CEO: Toshiharu Kurisu, Head office: Tokyo, Japan), which proposes new customer experiences through the digitization of fragrance, announced that their AI service that verbalizes fragrance KAORIUM has been selected as “Retracing innovation and ideas that defined the lifestyle trends of 2023” by STIRworld.com, a leading global digital magazine in the fields of design, architecture, and arts.
* KAORIUM is a registered trademark of SCENTMATIC Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328876250/en/
What's KAORIUM? Read scents, smell words; A journey of fragrance discovery that ignites the olfactory imagination. Finding a perfume is a challenge. Fragrances are hard to grasp, and expressing our preferences can be tough. KAORIUM by SCENTMATIC is an entirely novel approach to fragrance exploration that decodes the enigmatic world of scents and helps people discover new fragrances intuitively through language. Harnessing state-of-the-art technology, our mission is to deliver olfactory moments of delight. When a scent is placed on the coaster, the impression of the scent is visualized in words. By expressing sensory perceptions through language, scents that were once difficult to discern become more clearly perceivable. (Graphic: Business Wire)
STIRworld.com Article page (Published 17 December 2023)
“Retracing innovation and ideas that defined the lifestyle trends of 2023”
https://www.stirworld.com/see-features-retracing-innovation-and-ideas-that-defined-the-lifestyle-trends-of-2023
The article introduces KAORIUM as one of the lifestyle trends that will have a major impact on the global design structure in 2023. The article describes KAORIUM’s process of scent, language, and artificial intelligence uniting to refine the user's scent preferences as “an immersive experience”. KAORIUM was highly evaluated as a lifestyle trend for 2023, defining a new retail experience that cannot be found in traditional perfume selling counters.
About KAORIUM
https://www.youtube.com/embed/0fpDr3zgjeM?feature=oembed
The article was also featured on the Instagram account of STIRworld.com.
STIRworld.com Instagram reel video (Posted on 20 December 2023)
https://www.instagram.com/reel/C1CqKsNywAD/?igsh=cXJxczUzanhxa2to
KAORIUM was in the spotlight when we exhibited this AI system that mutually converts scents and words at the London Design Festival 2023, one of the world's leading design events, held in London, UK, for eight days from 16 to 24 September 2023.
STIRworld.com Article page (Published on 19 September 2023)
https://www.stirworld.com/see-lifestyle-scentmatics-kaorium-at-ldf-2023-explores-language-and-emotion-in-fragrance-selection
In the interview with STIR, Kurisu, Managing Director of SCENTMATIC, introduced the innovations brought by KAORIUM to the Japanese retail industry, as well as its future potential and social impact.
GET IN TOUCH
https://scentmatic.co.jp/contact-en
[SCENTMATIC, Inc.]
SCENTMATIC was established in 2019 as a co-creation fragrance business design group that can add "emotional experience value" to everything using an AI system that verbalizes fragrance. Focusing on the most unknown area of the five senses “smell”, we have developed KAORIUM, an AI tool that verbalizes fragrance. KAORIUM is expected to help businesses to utilize fragrance in a variety of ways. SCENTMATIC is working on the 'digitalization of the sense of smell'. It will revolutionize business in all industries by evolving people's senses through the 'experience of smell' using fragrance and words.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328876250/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom